Intrauterine Levonorgestrel Delivered By a Frameless System, Combined With Systemic Estrogen: Acceptability and Endometrial Safety After 3 Years of Use in Peri- and Postmenopausal Women

Abstract Objective. To evaluate the acceptability and endometrial safety of a novel intrauterine drug delivery system, FibroPlant- levonorgestrel (LNG), combined with estrogen therapy (ET) in 150 peri- and postmenopausal women, followed-up for at least 3 years. Design. This was a prospective, non-comparative study in peri- and postmenopausal women. In the majority of women, treatment with the FibroPlant-LNG intrauterine system (IUS), combined with ET, was initiated during the perimenopausal...